Publications

Featured Publications

Pattern of Natural Killer (NK) Cell (CD16+CD56+) Expansion Correlates With Response Outcomes With Nemvaleukin Alfa Treatment

Society for Immunotherapy of Cancer (SITC) Annual Meeting

calendar icon November 2023


>> View Poster

ARTISTRY-7: Phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer

Future Oncology

calendar icon June 2023


>> View Article

Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors: ARTISTRY-1

American Society of Clinical Oncology (ASCO) Annual Meeting

calendar icon


>> View Presentation

All Publications

  • Filter by Indications

  • Filter by Clinical Study

  • Reset Filters

Clinical Development of Nemvaleukin Alfa (ALKS 4230) for Advanced Solid Tumors With High Unmet Need: From Design to Bench to Bedside

Cytokines in Cancer Immunotherapy Workshop

calendar icon October 2021


>> View Poster

Antitumor Efficacy and Immune Profiling of the Mouse Ortholog of Nemvaleukin Alfa, a Novel Engineered IL-2 Fusion Protein, in an Orthotopic Mouse Model of Small Cell Lung Cancer Alone or in Combination with Standard Chemotherapy

European Society for Medical Oncology (ESMO) Congress

calendar icon September 2021


>> View Poster

ARTISTRY-6: Nemvaleukin Alfa Monotherapy in Patients With Advanced Mucosal and Cutaneous Melanoma

European Society for Medical Oncology (ESMO) Congress

calendar icon September 2021


>> View Poster

Pharmacokinetics and Pharmacodynamic Effects of Nemvaleukin Alfa, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, in Cynomolgus Monkeys

The Journal of Pharmacology and Experimental Therapeutics

calendar icon August 2021


>> View Article

A Phase 2 Clinical Trial of Nemvaleukin Alfa (ALKS 4230) Combined With Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC): the ION-01 Trial

American Head & Neck Society (AHNS) International Conference

calendar icon July 2021


>> View Poster

Nemvaleukin Alfa Monotherapy in Patients With Advanced Melanoma: ARTISTRY-1

European Association of Dermato Oncology (EADO) Congress

calendar icon April 2021


>> View Poster

Phase 1/2 Study of Subcutaneously Administered ALKS 4230, a Novel Engineered Cytokine, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors: ARTISTRY-2

Society for Immunotherapy of Cancer (SITC) Annual Meeting

calendar icon November 2020


>> View Poster

ALKS 4230: A Novel, Engineered Interleukin Variant Immunotherapy – Clinical Data Updates from ARTISTRY-1 Trial

European Society for Medical Oncology Virtual Congress 2020

calendar icon September 2020


>> View Presentation

The Combination of a Mouse Ortholog of ALKS 4230, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, and the Angiogenesis Inhibitor Lucitanib Enhances Antitumor Activity

American Association for Cancer Research Annual Meeting

calendar icon April 2020


>> View Poster

Clinical Outcomes of Ovarian Cancer Patients Treated With ALKS 4230, a Novel Engineered Cytokine, in Combination With Pembrolizumab: ARTISTRY-1 Trial

Society for Immunotherapy of Cancer (SITC) Annual Meeting

calendar icon April 2020


>> View Poster

ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy

Journal for ImmunoTherapy of Cancer

calendar icon March 2020


>> View Publication

ARTISTRY-2: A Phase 1/2 Study of Subcutaneously Administrated ALKS 4230 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Society for Immunotherapy of Cancer (SITC) Annual Meeting

calendar icon November 2019


>> View Poster